An improved process for preparation of fluxametamide

Abstract

The present invention relates to an improved process for the preparation of isoxazoline- substituted benzamide compound. More particularly, the present invention relates to process for the preparation of Fluxametamide of Formula (I), by readily available reagents. Further, the present invention relates to an agrochemical composition, wherein the composition comprises at least a bio-active effective amount of Fluxametamide of formula (I) as obtained by the process disclosed in present invention. Furthermore, the present invention also relates to a process for preparing the agrochemical composition comprising Fluxametamide of formula (I) of the present invention.

Description

[0001] AN IMPROVED PROCESS FOR PREPARATION OF FLUXAMETAMIDE

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to an improved process for the preparation of isoxazolinesubstituted benzamide compound. More particularly, the present invention relates to process for the preparation of Fluxametamide of Formula (I), by readily available reagents. The improved process in relation to the present invention is a consistently reproducible process, which results in high yield, purity of Fluxametamide apart from resulting into stable form of Fluxametamide.

[0004] BACKGROUND OF THE INVENTION

[0005] Fluxametamide, chemically known as 4-((5RS)-5-(3,5-dichlorophenyl)-4,5-dihydro-5- (trifluoromethyl)isoxazol-3-yl)-N-((EZ)-(methoxyimino)methyl)-o- toluamide is a novel wide-spectrum insecticide that was discovered and synthesized by Nissan Chemical Industries, Ltd. It belongs to a class of compounds called isoxazolines, which are potent inhibitors of y- aminobutyric acid (GABA), glutamate-, and glycine-gated chloride channels in insects. Fluxametamide has a structural formula as:

[0006] Structure of Fluxametamide

[0007] Formula (I)

[0008] Fluxametamide is a wide-spectrum isoxazoline insecticide effective against a broad spectrum of pests. It is mainly used in the control of lepidopteran pests, thrips, whiteflies, leaf miners, beetles and mites on crops such as fruit trees, vegetables, soybeans, cotton and tea trees and other crops.

[0009] Prior art documents are known which discloses the synthesis of isoxazolinederivative compounds, for instance: U.S. Patent No. 7,662,972 discloses the compound of Formula (I) and synthesis of isoxazoline-substituted benzamide compounds. The prior art discloses the use of toxic reagents like carbon monoxide thereby need special equipments which are not easy to operate. Further, it also needs extensive pollution abetment systems for effectively eliminating toxic chemicals which also leads to higher pollution load. Thus, the process in the prior art is more polluting, makes use of toxic and hazardous chemicals and special purpose equipments which makes it economically unattractive and also more polluting as compared to the process of the present invention. Thus, the disclosed process in the prior art is economically less viable.

[0010] Further, reference can also be made from an International (PCT) Publication number WO 2013 / 021949, which discloses methods for producing substituted 4,4-difluoro-2-buten-l-one compounds and substituted isoxazoline compounds by carrying out a dehydration reaction in the presence of a phase transfer catalyst.

[0011] However, the processes described in the prior arts are not suitable for an efficient large scale commercial production. Therefore, it is desirable to provide more economical, less hazardous, easy and commercially feasible process for the production of isoxazoline-substituted benzamide compound, Fluxametamide of Formula (I).

[0012] Hence, there is a need for an improved process for preparation of Fluxametamide that overcome the drawbacks of prior arts, therefore, the present invention conceived an improved process for the preparation of Fluxametamide of formula (I).

[0013] The present invention satisfies the existing needs, as well as others, and generally overcomes the deficiencies found in the prior arts.

[0014] OBJECTIVE AND ADVANTAGES OF INVENTION

[0015] The main objective of the present invention is to provide an improved, simple, economically advantageous and cost-effective process for the preparation of Fluxametamide of Formula (I), with high purity and yield of Fluxametamide on a commercial scale by readily accessible and very economical intermediates which are easy to handle.

[0016] Another objective of the present invention is to provide a novel and effective process for preparation of Fluxametamide of formula (I), with reduced or minimal waste generation.

[0017] Another objective of the present invention is to provide a process for the preparation of Fluxametamide of Formula (I), with an improved reaction rate and minimized side reaction and / or formation of by-products. Another objective of the present invention is to provide a process for the preparation of Fluxametamide of formula (I), that involves less expensive and readily available reagents and solvents.

[0018] Another objective of the present invention is to provide a process for the preparation of Fluxametamide of formula (I), which is industrially and economically robust process with safe operations

[0019] Another objective of the present invention is to provide a process for the preparation of Fluxametamide of formula (I), which results in improved yield and purity of the final product.

[0020] Another objective of the present invention is to provide an improved process for the preparation of Fluxametamide of Formula (I), in free form or in agro chemically acceptable salt which can be further utilized for formulating into suitable dosage forms.

[0021] Another objective of the present invention is to provide a process wherein, a cleaner product is obtained with minimum and / or no by-products formation.

[0022] Another objective of the present invention is to provide the process for the preparation of Fluxametamide of formula (I), its intermediates and process of preparation of intermediates involving milder conditions like moderate temperature and pressure.

[0023] Another objective of the present invention is to provide an industrially and economically robust process with safe operations.

[0024] Another objective of the present invention is to provide an improved process for preparation of a Fluxametamide of formula (I), by reacting the compound, 4-[5-(3,5-dichlorophenyl)-5- (trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-3) in the presence of formylating agent followed by treatment with methoxy-amine hydrochloride.

[0025] Another objective of the present invention is to obtain a compound, 4-[(2Z)-3-(3-chloro-5- nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2-methylbenzamide of Formula (C-l), by coupling a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A-3), with a compound, 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), using Wittig reaction or modified Wittig reaction or Witting Homer reaction.

[0026] Another objective of the present invention is to obtain a compound, 4-[5-(3-chloro-5- nitrophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2), by cyclizing a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4- trifluorobut-2-enoyl]-2-methylbenzamide of Formula (C-l), in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid mediated cyclization.

[0027] Another objective of the present invention is to obtain a compound, 4-[5-(3,5-dichlorophenyl)- 5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-3), by hydrogenating, the compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)-4,5-dihydro- l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2), in the presence of hydrogen and catalysts at suitable pressure and suitable solvents to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl.

[0028] Some or all these and other objects of the invention can be achieved by way of the invention described hereinafter.

[0029] Advantages of the present invention:

[0030] 1. The process, intermediates and process of preparation of intermediates of the present invention provides improved process utilizing less time, readily available reagent which are non-toxic and less / non-polluting without requiring any hazardous chemicals and special purpose equipments as used in the prior art documents

[0031] 2. The process of the present invention provides better yield with high purity intermediates as well as the final product.

[0032] 3. The process, intermediates, and process of preparation of intermediates of the present invention involves milder conditions like moderate temperature and pressure.

[0033] 4. Industrially and economically robust process with safe operations.

[0034] SUMMARY OF THE INVENTION

[0035] Accordingly, the main aspect of the present invention is to provide an improved process for the preparation of Fluxametamide of Formula (I), by readily accessible and cheap intermediates which are easy to handle. Provided herein is simple, cost effective and consistently reproducible process for the preparation of highly pure and stable form of Fluxametamide.

[0036] In an aspect, the present invention provides an alternative and improved process for the preparation of Fluxametamide of Formula (I), using cost effective and readily available reagents. In another aspect, the present invention provides a process for the preparation of Fluxametamide of Formula (I), in simple manner and in good yield and purity.

[0037] In another aspect, the present invention provides an improved process for the preparation of Fluxametamide of formula (I), its intermediates and process of preparation of intermediates involving milder conditions like moderate temperature and pressure.

[0038] In an aspect, the present invention provides an improved process for the preparation of Fluxametamide of Formula (I), comprising: a) reacting a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A-3), with a compound, 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), using Wittig reaction or modified Wittig reaction or Witting Horner reaction to obtain a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2- methylbenzamide of Formula (C-l); b) cyclizing the compound of Formula (C-l) in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid medicated cyclization to obtain a dihydroisoxazole compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)-4,5- dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2); c) reacting the compound of Formula (C-2) in the presence of hydrogen and catalysts at suitable pressure and in the presence of suitable solvents to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl to obtain a compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5- dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-3); and d) reacting the compound of Formula (C-3) in the presence of formylating agent followed by treatment with methoxyamine hydrochloride to obtain the target compound, Fluxametamide of formula (I).

[0039] In another aspect, the present invention provides a compound, 4-[(2Z)-3-(3-chloro-5- nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2-methylbenzamide of Formula (C-l), obtained by coupling a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A- 3), with a compound, 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), using Wittig reaction or modified Wittig reaction or Witting Homer reaction.

[0040] In another aspect, the present invention provides a compound, 4-[5-(3-chloro-5-nitrophenyl)- 5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2) is obtained by cyclizing a compound 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2- enoyl]-2-methylbenzamide of Formula (C-l), in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid mediated cyclization.

[0041] In another aspect, the present invention provides a compound, 4-[5-(3,5-dichlorophenyl)-5- (trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide (C-3), is obtained by hydrogenating, the compound 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)-4,5-dihydro- l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2), in the presence of hydrogen and catalysts at suitable pressure and in the presence of suitable solvents to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl.

[0042] In another aspect, the present invention provides a Fluxametamide of formula (I), by reacting the compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2- methylbenzamide of Formula (C-3) in the presence of formylating agent followed by treatment with methoxyamine hydrochloride.

[0043] DETAILED DESCRIPTION OF THE INVENTION

[0044] At the very outset of the detailed description, it may be understood that the ensuing description only illustrates a particular form of this invention. However, such a particular form is only exemplary embodiment, and without intending to imply any limitation on the scope of this invention. Accordingly, the description is to be understood as an exemplary embodiment and teaching of the invention and not intended to be taken restrictively.

[0045] The technical solutions of the present disclosure will be further described below by way of specific embodiments. It will be apparent to those skilled in the art that the embodiments are merely illustrations of the present disclosure and should not be construed as specific limitations to the present disclosure.

[0046] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the present disclosure.

[0047] Certain ranges are presented herein with numerical values being preceded by the term “about”. The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximately unrecited number may be a number which in the context in which it is presented, provides the substantial equivalent of the specifically recited number. In an embodiment, “about” can mean within one or more standard deviations, or within ±30%, 25%, 20%, 15%, 10%, or 5% of the stated value.

[0048] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any process and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred process is described. For the purposes of the present invention, the following terms are defined below:

[0049] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0050] As used herein, the terms, “including”, “includes”, “comprising”, and comprises” mean “including without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items.

[0051] Each embodiment is provided by way of explanation of the invention and not by way of limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the process described herein without departing from the scope of the invention. For instance, features illustrated or described as part of one embodiment can be applied to another embodiment to yield a still further embodiment.

[0052] While several embodiments of the present invention have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and / or structures for performing the functions and / or obtaining the results and / or one or more of the advantages described herein, and each of such variations and / or modifications is deemed to be within the scope of the present invention.

[0053] Moreover, other than in any operating examples, or where otherwise indicated, all numbers expressing, for example, quantities of materials / ingredients used in the specification are to be understood as being modified in all instances by the term "about". The term "about" shall be interpreted to mean "approximately" or "reasonably close to" and any statistically insignificant variations therefrom. Conventional methods for the preparation of fluxametamide are associated with drawbacks such as use of toxic reagents like carbon monoxide, special equipments which are not easy to operate with no suggestion of high purity. Further, these conventional processes and equipments make the process uneconomical.

[0054] The main embodiment of the present invention is to provide an improved process for the preparation of Fluxametamide of Formula (I), comprising: a) reacting a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A-3), with a compound, 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), using Wittig reaction or modified Wittig reaction or Witting Horner reaction to obtain a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2- methylbenzamide of Formula (C-l); b) cyclizing the compound of Formula (C-l) in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid mediated cyclization to obtain a dihydroisoxazole compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)-4,5- dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2); c) reacting the compound of Formula (C-2) in the presence of hydrogen and catalysts at suitable pressure and in the presence of a suitable solvent to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl to obtain a compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5- dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-3); and d) reacting the compound of Formula (C-3) in the presence of formylating agent followed by treatment with methoxyamine hydrochloride to obtain the target compound, Fluxametamide of formula (I).

[0055] In one of the embodiments, the process involves coupling a compound, l-(3-chloro-5- nitrophenyl)-2,2,2-trifluoroethan-l-one (A-3), with a compound, 4-(2-bromoacetyl)-2- methylbenzamide of Formula (B-4), using Wittig reaction or modified Wittig reaction or Witting Horner reaction to obtain a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4- trifluorobut-2-enoyl]-2-methylbenzamide of Formula (C-l), (Scheme-1).

[0056] In an embodiment, a compound of Formula (A-3), i.e., l-(3-chloro-5-nitrophenyl)-2,2,2- trifluoroethan-l-one is obtained by sequential reactions starting from Nitrobenzene of Formula (A-l) (Scheme 2). Subjecting a compound, Nitrobenzene of Formula (A-l) to acylation in the presence of acylating agent and Lewis acids, to furnish the compound, of Formula (A-2), i.e., 2,2,2-trifluoro- 1 -(3-nitrophenyl)ethan- 1 -one.

[0057] In one of the embodiments, the compound of Formula (A-2) is reacted in the presence of halogenating agent to furnish a compound of Formula (A-3), i.e., l-(3-chloro-5-nitrophenyl)- 2,2,2-trifluoroethan- 1 -one.

[0058] In an embodiment, a compound of Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide is obtained by sequential reactions from o-Xylene of Formula (B-l) (Scheme 3). The compound of Formula (B-l) is subjected to acylation in the presence of an acylating agent and lewis acids to furnish a compound of Formula (B-2), i.e., l-(3,4-dimethylphenyl)ethan-l-one.

[0059] In one of the embodiments, the compound of Formula (B-2) after suitable protection of carbonyl group under controlled oxidative conditions known to the person skilled in the art provides the corresponding acid which is converted to the acid chloride in the presence of halogenating agents and suitable solvents followed by amidation to furnish a compound of Formula (B-3), i.e., 4-acetyl-2-methylbenzamide. The compound of Formula (B-3) is subjected to halogenation in the presence of halogenating agents and a suitable solvent to provide a compound of Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide.

[0060] In an embodiment, the key intermediate of Formula (C-l), i.e., 4-[(2Z)-3-(3-chloro-5- nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2-methylbenzamide is cyclized using hydroxylamine hydrochloride in the presence of a suitable solvent followed by acid mediated cyclization to yield dihydroisoxazole compound of Formula (C-2), i.e., 4-[5-(3-chloro-5-nitrophenyl)-5- (trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide, (Scheme-4).

[0061] In one of the embodiments, the dihydroisoxazole compound of Formula (C-2) is hydrogenated in the presence of hydrogen and catalysts and in suitable solvent to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl to provide a compound of Formula (C-3), i.e., 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)- 4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide. The compound of Formula (C-3) is formylated in the presence of formylating agent in-situ followed by treatment with methoxy amine hydrochloride to furnish the target compound, i.e., Fluxametamide of formula (I)-

[0062] In another embodiment, the present invention provides an improved process for the preparation of Fluxametamide of Formula (I), comprising obtaining the key intermediate of Formula (C- 1), i.e., 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2-methylbenzamide by the coupling reaction between compounds of Formula (A-3), i.e., l-(3-chloro-5-nitrophenyl)- 2,2,2-trifluoroethan-l-one and Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide using the reaction like but not limited to Wittig reaction or modified Wittig reaction or Witting Homer reaction (Scheme 1).

[0063] Scheme 1:

[0064] The compound of Formula (A-3) is obtained by the sequential reactions starting from nitrobenzene of Formula (A-l), (Scheme 2), wherein, nitrobenzene (A-l) is subjected to acylation in the presence of trifluoroacetyl chloride or trifluroacetic anhydride in the presence of lewis acids selected from the group comprising Aluminium chloride, Zinc Chloride, Ferric chloride, any metal triflates or Zeolites, to furnish the compound of Formula (A-2), i.e., 2,2,2- trifluoro- l-(3-nitrophenyl)ethan- 1-one.

[0065] A-2

[0066] The compound of Formula (A-2) is chlorinated in the presence of chlorinating agents selected from the group comprising chlorine gas or chlorine in combination with acetic acid or N- chlorosuccinimide or combination thereof to furnish a compound of Formula (A-3), i.e., l-(3- chloro-5-nitrophenyl)-2,2,2-trifluoroethan- 1 -one. Scheme 2:

[0067] (CF3CO)2O &

[0068] A-1 A-2 A-3

[0069] In an embodiment, a compound of Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide is obtained by sequential reactions from o-Xylene of Formula (B-l) (Scheme 3), wherein, o- Xylene of Formula (B-l) is subjected to acylation in the presence of an acetyl chloride or acetic anhydride in the presence of lewis acids selected from the group comprising Aluminium chloride, Zinc Chloride, Ferric chloride, any metal triflates or Zeolites or combination thereof to furnish a compound of Formula (B-2), i.e., l-(3,4-dimethylphenyl)ethan-l-one.

[0070] B-2

[0071] The compound of Formula (B-2) after suitable protection of the carbonyl group under controlled oxidative conditions known to the person skilled in the art provides the corresponding acid which is converted to the acid chloride using chlorinating agents selected from the group comprising of thionyl chloride, oxalyl chloride, phosphorous trichloride or phosphorous pentachloride, Cuprous chloride in suitable solvents like ethylene dichloride (EDC), methylene dichloride (MDC), chlorobenzene followed by amidation with ammonia gas, or aqueous ammonia or ammonium acetate or ammonium formate to furnish a compound of Formula (B-3), i.e., 4-acetyl-2-methylbenzamide.

[0072] Scheme 3: 1 . MEG, p-TSA

[0073] The compound of Formula (B-3) is subjected to bromination in the presence of brominating agents selected from the group comprising of an aqueous HBr, KBr, or A-bromosuccinimide (NBS) in combination with H2O2 & H2SO4 and the suitable solvent to provide a compound of

[0074] Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide.

[0075] B-4

[0076] The key intermediate thus obtained is converted into Fluxametamide by the series of the transformations (Scheme 4).

[0077] Scheme 4:

[0078] C-3 Fluxamitamide

[0079] The key intermediate of Formula (C-l), i.e., 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4- trifluorobut-2-enoyl]-2-methylbenzamide is cyclized in the presence of hydroxylamine hydrochloride in the suitable solvent followed by acid mediated ring cyclization to yield a dihydroisoxazole compound of Formula (C-2), i.e., 4-[5-(3-chloro-5-nitrophenyl)-5- (trifluoromethyl)-4,5-dihydro- 1 ,2-oxazol-3-yl] -2-methylbenzamide.

[0080] The dihydroisoxazole compound of Formula (C-2) is hydrogenated in the presence of hydrogen and catalysts like 5-10% Pd on charcoal or 5% Pt on charcoal or by transfer hydrogenation either at atmospheric pressure or in autoclave up to 50 Bar pressure in suitable solvents like methanol, ethyl acetate, acetic acid or combination thereof to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl to provide a compound of Formula (C-3), i.e., 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5- dihydro- 1 ,2-oxazol-3 -yl] -2-methylbenzamide.

[0081] C-3

[0082] The compound of Formula (C-3) is formylated using phosphorous oxychloride and N,N- Dimethylformamide followed by treatment with methoxyamine hydrochloride to furnish the target compound, Fluxametamide of Formula (I).

[0083] The following is the reaction scheme of the process of the present invention:

[0084] (CF3CO)2O &

[0085] C-3 Fluxamitamide

[0086] In one of the embodiments, a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4- trifluorobut-2-enoyl]-2-methylbenzamide of Formula (C-l), is obtained by coupling a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A-3), with a compound, 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), using Wittig reaction or modified Wittig reaction or Witting Homer reaction.

[0087] In one of the embodiments, a compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)- 4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2), is obtained by cyclizing a compound 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2- methylbenzamide of Formula (C-l), in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid mediated cyclization. In one of the embodiments, a compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5- dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-3), is obtained by hydrogenating, the compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3- yl]-2-methylbenzamide of Formula (C-2), in the presence of hydrogen and catalysts at suitable pressure and in the presence of suitable solvents to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with CuCl.

[0088] In one of the embodiments, a Fluxametamide of formula (I), is obtained by formylating the compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2- methylbenzamide of Formula (C-3) in the presence of formylating agent followed by treatment with methoxyamine hydrochloride.

[0089] In one of the embodiments, the base is selected from the group comprising di-isopropylamine, diisopropylethylamine, tri-ethylamine, dimethylamine, trimethyl amine, pyridine, N- methylmorpholine, 3-picoline, 2-picoline, 4-picoline, sodium hydroxide, potassium hydroxide, n-butyl lithium, sodium carbonate, sodium bicarbonate, potassium carbonate, or their bicarbonate salts, calcium hydroxide, Sodium methoxide , sodium acetate, or combination thereof.

[0090] In one of the embodiments, the acylating agent is selected from the group comprising Trifluoroacetyl chloride or trifluoroacetic anhydride, Trifluoroacetic acid, acetyl chloride, acetic anhydride or combination thereof.

[0091] In one of the embodiments, the oxidization in the process of the present invention is by utilizing oxidising agent for instance but not limited to oxygen, with or without a suitable catalyst.

[0092] In one of the embodiments, the lewis acid is selected from the group comprising Zinc chloride (ZnCh), Aluminium Chloride (AICI3), Ferric Chloride (FeCF), Boron Trifluoride (BF3), Boron Trichloride (BCI3), Titanium tetrachloride (TiCU), Antimony Pentafluoride (SbFs), Copper Chloride (CuCh), any metal triflates or Zeolites or combination thereof.

[0093] In one of the embodiments, the halogenating agent is selected from the group comprising chlorine gas or N-Chlorosuccinimide, Thionyl chloride, Oxalyl chloride, phosphorus tribromide, X2, HX, wherein X = Cl, Br, I, Phosphorous trichloride, sulfuryl chloride or phosphorous pentachloride, Cuprous chloride or chlorine, bromine, fluorine, iodine in combination with acetic acid, hydrogen, H2O2, potassium, and H2SO4 or combination thereof. In an embodiment, the halogenating agent is selected from chlorinating agent or brominating agent.

[0094] In one of the embodiments, the suitable solvent is selected from the group comprising ethylene dichloride (EDC), methylene dichloride (MDC), chlorobenzene, methanol, ethyl acetate, acetic acid, N,N-dimethylformamide (DMF), benzene, chloroform, 1, 4-dioxane, diethyl ether, acetic acid, hydrogen peroxide, o-dichlorobenzene, carbon tetrachloride, chlorobenzene, dichlorobenzene, tetrahydrofuran and acetonitrile, acetone, dimethylsulfoxide, cyclohexane, hexane, heptane, toluene, xylene, phosphorous oxychloride , isopropanol, 2-propanol, ethylene chloride, Tetrahydrofuran (THF), toluene, brine, sodium sulfate, other metal sulfates or combination thereof.

[0095] In one of the embodiments, the formylating agent is selected from the group comprising paraformaldehyde, formalin, formic acid, methyl formate, A, AAli methyl formamide, diazomethane, cyanogen bromide, hydrogen cyanide, phosphorous oxychloride or combination thereof. In one of the embodiments, the amidation is carried by the reagents selected from the group comprising ammonia gas, or aqueous ammonia or ammonium acetate or ammonium formate or combination thereof.

[0096] In one of the embodiments, the suitable reagents are selected from the group comprising Monoethylene glycol (MEG), Sodium nitritre, triphenylphosphine or mixtures thereof. In one of the embodiments, the catalyst of the present invention is selected from the group comprising 5-10% Pd on Charcoal or 5%Pt on Charcoal, ZSM-5, p-Toluenesulfonic acid (p- TSA), Cobalt (II) acetylacetone [(Co(acac)2], Tetra-n-butyl ammonium bromide (TBAB), (Azobisisobutyronitrile) AIBN or combination thereof.

[0097] In one of the embodiments, an improved process for the preparation of Fluxametamide of Formula (I), comprising: i. reacting a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A-3), with 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), to obtain a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2- enoyl]-2-methylbenzamide of Formula (C-l); ii. cyclizing the compound of Formula (C-l) in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid mediated cyclization to obtain a dihydroisoxazole compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)- 4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2); iii. hydrogenating the compound of Formula (C-2) in the presence of hydrogen and catalysts at suitable pressure and in the presence of a suitable solvent to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with chlorinating agent such as CuCl to obtain a compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2- methylbenzamide of Formula (C-3); and iv. reacting the compound of Formula (C-3) in the presence of formylating agent followed by treatment with methoxyamine hydrochloride to obtain the target compound, Fluxametamide of formula (I).

[0098] In one of the embodiments, an improved process for the preparation of compound of l-(3- chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one i.e., compound of Formula (A-3) as disclosed in the present invention, comprises: v. subjecting a compound, Nitrobenzene of Formula (A-l) to acylation in the presence of acylating agent and Lewis acids, to furnish a compound, of Formula (A -2), i.e.,

[0099] 2.2.2-trifluoro-l-(3-nitrophenyl)ethan-l-one; vi. reacting the compound of Formula (A-2), obtained in step (i) with halogenating agent to furnish a compound of Formula (A-3), i.e., l-(3-chloro-5-nitrophenyl)-

[0100] 2.2.2-trifluoroethan- 1 -one;

[0101] In one of the embodiments, an improved process for the preparation of compound of Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide as disclosed in the present invention, comprises: i. subjecting a compound o-Xylene of Formula (B-l) to acylation in the presence of an acylating agent and lewis acids to furnish a compound of Formula (B-2), i.e., 1- (3 ,4-dimethylphenyl)ethan- 1 -one. ii. converting the compound of Formula (B-2) obtained in step (i) to its acid chloride in the presence of halogenating agents and suitable solvents after suitably protecting the carbonyl group of compound of Formula (B-2) under controlled oxidative conditions, followed by amidation to furnish a compound of Formula (B-3), i.e., 4- acetyl-2-methylbenzamide. iii. subjecting the compound of Formula (B-3) obtained in step (ii) to halogenation in the presence of halogenating agents and a suitable solvent to provide a compound of Formula (B-4), 4-(2-bromoacetyl)-2-methylbenzamide.

[0102] In one of the embodiments, the acylating agent is selected from the group comprising Acetyl chloride, Acetic anhydride, Trifluoroacetyl chloride or trifluoroacetic anhydride, Trifluoroacetic acid or combination thereof.

[0103] In one of the embodiments, the lewis acid is selected from the group comprising Zinc chloride (ZnCh), Aluminium Chloride (AICI3), Ferric Chloride (FeCh), Boron Trifluoride (BF3), Boron Trichloride (BCI3), Titanium tetrachloride (TiCU), Antimony Pentafluoride (SbFs), Copper Chloride (CuCh), p-Toluenesulfonic acid (p-TSA) any metal triflates or Zeolites or combination thereof.

[0104] In one of the embodiments, the halogenating agent is selected from the group comprising of a chlorinating agent, brominating agent, fluorine, iodine, etc. or combination thereof.

[0105] In one of the embodiments, the chlorinating agent is selected from the group comprising chlorine gas or chlorine in combination with acetic acid, thionyl chloride, oxalyl chloride, phosphorous trichloride or phosphorous pentachloride, or A-chlorosuccinimide, Cuprous chloride or combination thereof.

[0106] In one of the embodiments, the brominating agent is selected from the group comprising of an aqueous HBr, KBr, or A-bromo succinimide (NBS) in combination with H2O2 & H2SO4 or combinations thereof.

[0107] In one of the embodiments, the halogenating agent is further selected from selected from the group comprising chlorine gas or N-Chlorosuccinimide, Thionyl chloride, Oxalyl chloride, phosphorus tribromide, X2, HX, wherein X = Cl, Br, I, Phosphorous trichloride, sulfuryl chloride or phosphorous pentachloride, Cuprous chloride or chlorine, bromine, fluorine, iodine in combination with acetic acid, hydrogen, H2O2, potassium, and H2SO4 or combination thereof.

[0108] In one of the embodiments, the suitable solvent is selected from the group comprising ethylene dichloride (EDC), methylene dichloride (MDC), chlorobenzene, methanol, ethyl acetate, acetic acid, N-dimethylformamide, benzene, chloroform, 1, 4-dioxane, diethyl ether, hydrogen peroxide, o-dichlorobenzene, carbon tetrachloride, chlorobenzene, dichlorobenzene, tetrahydrofuran and acetonitrile, acetone, dimethylsulfoxide, cyclohexane, hexane, heptane, toluene, xylene, phosphorous oxychloride , isopropanol, 2-propanol, ethylene chloride, Tetrahydrofuran (THF), toluene, brine, sodium sulfate, other metal sulfates or combination thereof.

[0109] In one of the embodiments, the process of acid-mediated cyclization is carried by using mineral acid such as HC1.

[0110] In one of the embodiments, the suitable pressure is in range from the atmospheric pressure to 50 Bar pressure.

[0111] In one of the embodiments, the formylating agent is selected from the group comprising paraformaldehyde, formalin, formic acid, methyl formate, phosphorous oxychloride, N,N- dimethylformamide, diazomethane, cyanogen bromide, hydrogen cyanide or combination thereof.

[0112] In one of the embodiments, the process of amidation is carried by the reagents selected from the group comprising ammonia gas, or aqueous ammonia or ammonium acetate or ammonium formate or combination thereof.

[0113] In one of the embodiments, the catalyst is selected from the group comprising 5-10% Pd on Charcoal or 5% Pt on Charcoal, ZSM-5, p-Toluenesulfonic acid (p-TSA), Cobalt (II) acetylacetone [(Co(acac)2] , Tetra-n-butyl ammonium bromide (TBAB), (Azobisisobutyronitrile) AIBN or combination thereof.

[0114] In one of the embodiments, the process for preparing agrochemical composition comprising Fluxametamide of Formula (I) as obtained by the process as disclosed in the present invention.

[0115] In one of the embodiments, an agrochemical composition, wherein the composition comprises at least a bio-active effective amount of Fluxametamide of Formula (I) as obtained by the process as disclosed in the present invention. In one of the embodiments, the agrochemical composition as disclosed, further comprises one of more agrochemically acceptable excipients.

[0116] In one of the embodiments, a process for preparing the agrochemical composition comprising Fluxametamide of Formula (I) as disclosed in the present invention.

[0117] The process for preparing Fluxametamide of formula (I) according to the present invention gave Fluxametamide with purity of 95% to 99% and a yield of above 80%.

[0118] Below are the references for the compounds involved in the process of the present invention: A-l: Nitrobenzene;

[0119] A-2: 2,2,2-trifluoro-l-(3-nitrophenyl)ethan- 1-one or 2,2,2-Trifluoro-l-(3-nitro-phenyl)- ethanone;

[0120] A-3: l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one or l-(3-Chloro-5-nitro-phenyl)- 2,2,2-trifluoro-ethanone;

[0121] B-l: o-xylene;

[0122] B-2: l-(3,4-dimethylphenyl)ethan-l-one or l-(3,4-Dimethyl-phenyl)-ethanone;

[0123] B-3: 4-acetyl-2-methylbenzamide;

[0124] B-4: 4-(2-bromoacetyl)-2-methylbenzamide;

[0125] C-l: 4-[3-(3-Chloro-5-nitro-phenyl)-4,4,4-trifluoro-but-2-enoyl]-2-methyl-benzamide or 4- [(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2-enoyl]-2-methylbenzamide ;

[0126] C-2: 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2- methylbenzamide or 4-[5-(3-Chloro-5-nitro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol- 3 -yl] -2-methyl-benzamide;

[0127] C-3: 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2- methylbenzamide or 4-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3- yl]-2-methyl-benzamide;

[0128] Formula (I): Fluxametamide

[0129] In another embodiment, the process of preparation of 2,2,2-Trifluoro-l-(3-nitro-phenyl)- ethanone (A-2), comprises of Method A; or Method B, wherein Method A comprises:

[0130] A reactor fitted with different apparatus for instance but not limited to condenser, pockets comprising thermometer, thermometer, stirrer, tube and is charged with suitable solvent followed by nitrobenzene. Suitable Catalyst (including but not limited to ZSM-5) is added. Acylating agent is added drop wise over 20-40 mins and then the reaction mass is refluxed for 6-10 hrs. After completion of the reaction, the reaction mass is filtered and the filtrate is poured slowly over saturated sodium bicarbonate solution and stirred for 20-45 mins. The organic layer is separated. Aqueous layer is washed with suitable solvents like EDC. The combined organic layer is washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish 2,2,2-Trifluoro-l-(3-nitro-phenyl)-ethanone (A-2). After purification, purity and yield are calculated . Purity is found to be above 94%, and Yield above 75 %.

[0131] In another embodiment, the process of preparation of 2,2,2-Trifluoro-l-(3-nitro-phenyl)- ethanone (A-2), using Method B comprises:

[0132] A reactor fitted with different apparatus for instance but not limited to condenser, pockets comprising thermometer, thermometer, stirrer, tube and is charged with suitable solvent followed by nitrobenzene. Suitable catalyst is added. Suitable acylating agent (such as Trifluoroacetic acid) is added dropwise over 30mins to 1 hr and then the reaction mass is refluxed for 15-20 hrs. After completion of the reaction, the reaction mass is filtered and the filtrate was poured slowly over saturated sodium bicarbonate solution and stirred for 20-45 mins. The organic layer is separated. Aqueous layer is washed with suitable solvents. The combined organic layer is washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish 2,2,2-Trifluoro-l-(3-nitro-phenyl)-ethanone (A-2). After purification, purity and yield are calculated. Purity is found to be above 94%, and yield above 58 % .

[0133] In another embodiment, the process of preparation of l-(3-Chloro-5-nitro-phenyl)-2,2,2- trifluoro-ethanone (A-3) comprises:

[0134] A pressure reactor is charged with suitable solvent followed by 2,2,2-Trifluoro-l-(3-nitro- phenyl)-ethanone (A-2). Lewis acid is added. The reactor is filled with halogenating agent and the pressure of halogenating agent was held at 4-8 Bar. The reaction is heated to 100-140 deg C for 14-18 hrs under constant stirring. After completion of the reaction, the excess halogenating agent is quenched. Suitable solvent is added to the reaction mass and it is poured slowly over base (including but not limited to sodium hydroxide) and stirred for 20-45 mins. The organic layer is separated. Aqueous layer is washed with suitable solvent. The combined organic layer is washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish l-(3-Chloro-5-nitro-phenyl)-2,2,2-trifluoro-ethanone (A-3). After purification, purity and yield are calculated. Purity is found to be above 91%, Yield above 64%.

[0135] In another embodiment, the process of preparation of l-(3,4-Dimethyl-phenyl)-ethanone (B-2) comprises:

[0136] A reactor fitted with apparatus such as condenser, thermometer pocket, thermometer, mechanical stirrer, calcium chloride guard tube and is charged with suitable solvent followed by o-Xylene (B-l) and lewis acid (including but not limited to Aluminum chloride). The mixture is cooled to 5-12 deg C. Acylating agent is added dropwise over 30 mins to Ihr under vigorous stirring. After complete addition of acylating agent, the reaction mass is allowed to warm to room temperature and stirred for 3-4 hrs. After completion of the reaction, the reaction mass is slowly poured over ice-cold acid (for instance but not limited to HC1). After complete quenching, the mass is brought to room temperature. Organic layer is separated. The aqueous layer is washed with suitable solvent. The combined organic layer is washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish) l-(3,4-Dimethyl- phenyl)-ethanone (B-2). After purification, purity and yield are calculated. Purity is found to be above 91%, and yield above 77 %.

[0137] In another embodiment, the process of preparation of 4-Acetyl-2-methylbenzamide (B-3), comprises:

[0138] A reactor fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, calcium chloride guard tube is charged with suitable solvent followed by l-(3,4-Dimethyl-phenyl)- ethanone (B-2), Suitable reagent (for instance Monoethylene glycol) , and catalysts and lewis acid for instance (p-Toluenesulfonic acid (p-TSA)) .The reaction mass is heated to 60-85 deg C for 6-8 hrs. After completion of the reaction, the reaction mass is cooled to room temperature, quenched with addition of water. The organic layer is separated and washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to furnish 2- (3, 4-Dimethyl-phenyl)-2-methyl-[ 1,3] dioxolane (Crude material) (ketal derivative of B-2). The crude material is used without further purification for the next conversion which comprises a pressure reactor charged with suitable solvent for instance but not limited to acetic acid followed by 2-(3,4-Dimethyl-phenyl)-2-methyl-[l,3]dioxolane followed by suitable catalyst for instance Cobalt (II) acetylacetone [(Co(acac)2] , Tetra-n-butyl ammonium bromide (TBAB) . The pressure reactor is closed. The stirring is started. The reactor is flushed twice with gases such as oxygen or alike oxidating agent. The reactor is filled with oxygen and pressure is taken upto 7 bar. The reactor was heated to 100-120° C. After attaining the temperature, oxygen pressure is elevated up to 12 Bar. The reaction is continued for 8-10 hrs till completion. After completion of the reaction, the reactor is cooled down to room temperature, excess oxygen is bubbled through water before opening of the reactor. Solvent (for instance but not limited to acetic acid) is distilled out and the residue is poured on cold base solution (such as NaOH). The aqueous layer is washed with suitable solvent. The aqueous layer is acidified with concentrated acid at lower temperature. The solid obtained is filtered and dried till constant weight to furnish 4-Acetyl-2-methyl-benzoic acid. Purity is found to be above 97% and yield above 68 % .

[0139] Further, a reactor fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, Calcium chloride guard tube is charged with 4-Acetyl-2-methyl-benzoic acid (formed herein above reaction) dissolved in suitable solvent, followed by reaction with formylating agent at room temperature. Halogenating agent is added dropwise over 35-60 mins under vigorous stirring at room temperature. After complete addition of halogenating agent, the reaction mass is refluxed briefly (0.5 hr to 2 hr) to ensure complete conversion of acid to its acid chloride. The reaction mass is cooled to rt and diluted with additional suitable solvent. The process of amidation occurs by adding reagents (such as aqueous ammonia). The complete reaction sequence is performed in ventilated fume-hood. After completion of the reaction, it is quenched at lower temperature. The Organic layer is separated. Aqueous layer is washed with suitable solvent. The combined organic layer is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to furnish 4-Acetyl-2- methylbenzamide (B-3). After purification, purity is found to be above 96%, and yield above 84 %.

[0140] In another embodiment, the process of preparation of 4-(2-Bromo-acetyl)-2-methyl-benzamide (B-4), comprises:

[0141] A reactor fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, Calcium chloride guard tube is charged with 4-Acetyl-2-methylbenzamide dissolved in suitable solvent followed by catalyst for instance but not limited to (Azobisisobutyronitrile) AIBN. Halogenating agent is added portion-wise at 35-50° C. After complete addition of halogenating agent, the reaction mass is stirred for 7-9 hr. After completion of the reaction, the reaction mass is filtered and the residue is washed with solvent. The combined filtrate is washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated at reduced pressure to furnish 4-(2-Bromo-acetyl)-2-methyl-benzamide (B-4). After purification, purity is found to be above 91%, yield above 75% .

[0142] In another embodiment, the process of preparation of 4-[3-(3-Chloro-5-nitro-phenyl)-4,4,4- trifluoro-but-2-enoyl]-2-methyl-benzamide (C-l), comprises:

[0143] A flask fitted with thermometer pocket, thermometer, mechanical stirrer was charged with suitable solvent followed by reagent such as triphenylphosphine under nitrogen atmosphere. 4- (2-Bromo-acetyl)-2-methyl-benzamide is dissolved in suitable solvent and added in single lot at room temperature. Base is added in different equal portions at RT. A deep yellow to brown colored reaction mass is observed. After complete addition of base, the reaction mass is stirred for 10-20 mins followed by dropwise addition of l-(3-Chloro-5-nitro-phenyl)-2,2,2-trifluoro- ethanone (A-3) dissolved in solvent. The gradual decolorization of the reaction is seen indicating the reaction progress. After stirring for 2 hr, the reaction is slowly poured on ice- cold brine solution. The organic layer is separated. Brine layer is washed with suitable solvent. The combined organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to furnish 4-[3-(3-Chloro-5-nitro-phenyl)-4,4,4-trifluoro-but-2-enoyl]-

[0144] 2-methyl-benzamide (C-l). After purification, purity is found to be above 96%, yield above 81%.

[0145] In another embodiment, the process of preparation of 4-[5-(3-Chloro-5-nitro-phenyl)-5- trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl-benzamide (C-2), comprises:

[0146] A reactor fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, is charged with aqueous solution of hydroxylamine hydrochloride followed by base such as aqueous sodium hydroxide. This mixture is cooled to 5 to 10° C. (C-l) (144.3 g) and dissolved in suitable solvent like methanol which is added dropwise without allowing the reaction temperature to rise above a certain temperature. After complete addition, the reaction mass is allowed to warm to room temperature and stirred for 1.5-3 hrs. The reaction mass is cooled again to certain temperature and acid such as HC1 is added slowly. After complete addition, the reaction mass is allowed to warm to room temperature and then heated to high temperature range of 70-90° C for 6-8 hrs. After completion of the reaction, the pH of the reaction mass is adjusted to 8 to obtain 4-[5-(3-Chloro-5-nitro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-

[0147] 3-yl]-2-methyl-benzamide (C-2) as solid. The solid material is filtered, dried and recrystallized from solvent for instance but not limited to Isopropanol (IPA). After purification, purity is found to be above 95%, and yield above 70%.

[0148] In another embodiment, the process of preparation of 4-[5-(3,5-Dichloro-phenyl)-5- trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl-benzamide (C-3), comprises:

[0149] An autoclave reactor with 4-[5-(3-Chloro-5-nitro-phenyl)-5-trifluoromethyl-4,5-dihydro- isoxazol-3-yl]-2-methyl-benzamide (C-2) is charged and followed by suitable solvent, catalyst is also charged carefully to this mixture. The autoclave is closed and then flushed with Nitrogen gas several times. Nitrogen gas is removed by applying a slight vacuum and then filled with Hydrogenating agent such as Hydrogen gas. The pressure of hydrogen gas applied is around 5 Kg / cm2. Stirring is started and continued. Whenever, the pressure of hydrogenating agent (hydrogen) drops below 5 Kg / cm2, hydrogen gas is refilled to make up the pressure. After completion of the reaction, hydrogen gas is vented out very carefully in water container. The reaction mass is filtered through filtration aid such as celite and washed with suitable solvent like methanol. Combined methanolic layer is concentrated under vacuum to furnish 4-[5-(3- Amino-5-chloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl-benzamide (crude material). This crude material is used for the next step.

[0150] Further, in a reactor fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, 4-[5-(3-Amino-5-chloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2- methyl-benzamide is dissolved in acid (such as HC1) and cooled to 0- 5° C. Reagent for instance but not limited to Sodium nitrite in water is added dropwise without allowing the reaction mass temperature to rise above certain temperature. After completion of the addition, the reaction is maintained at the same temperature for 20-45 mins. Halogenating agent, such as chlorinating agents (for instance Cuprous chloride) is added in lots at the same temperature. After addition of chlorinating agent, the reaction is allowed to warm to room temperature and monitored by TLC and HPLC. Evolution of Nitrogen was seen. After completion, solvent is added and the organic layer is separated. The aqueous layer is washed with suitable solvent. The combined organic layer is washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish 4-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3- yl]-2-methyl-benzamide (C-3). After purification, purity is found to be above 94%, yield found to be above 74% .

[0151] In another embodiment, the process of preparation of Fluxametamide (I), comprises:

[0152] A flask fitted with thermometer pocket, thermometer, mechanical stirrer, anhydrous calcium chloride guard tube is charged with formylating agent (such as DMF). The flask is ice cooled and Phosphorous oxychloride (POC13) is added dropwise. An exothermic reaction occurs with the formation of the phosphorus oxychloride-dimethylformamide complex. After complete addition of POC13, the reaction mass is stirred for 10-20 mins in ice bath followed by addition of 4-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl- benzamide dissolved in DMF. The reaction is allowed to warm to room temperature and then heated at 70-900C. After completion of the reaction, the reaction mass is carefully poured on crushed ice with continuous stirring. The pH of the solution is adjusted to above 7 (range of 7- 8.5) by addition of base such as sodium acetate. The product is extracted in suitable solvent. The organic layer is washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated to furnish the residue.

[0153] The residue is dissolved in suitable solvent and cooled. Methoxylamine hydrochloride is added as a solid. To this mixture, base such as (sodium hydroxide) in water is added dropwise. The reaction is allowed to warm to room temperature and stirred for 4 hr. After completion, the obtained solid is filtered and washed with water, followed by washing with suitable solvent to furnish crude Fluxametamide. The product was crystallized from solvent such as 2-propanol twice. After purification, purity is found to be above 98 %, and yield above 84 %

[0154] According to another aspect, there is provided a process for preparing agrochemical composition comprising highly pure and stable Fluxametamide of formula (I)obtained as per the process disclosed herein. Yet in another embodiment, agrochemical compositions comprise at least a bio-active effective amount of highly pure and stable Fluxametamide of formula (I)obtained by the processes disclosed herein. The agrochemical compositions further contain one or more agrochemically acceptable excipients. Suitable excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.

[0155] While preferred embodiments and examples have been shown and described, it is to be understood that various further modifications will be apparent to those skilled in the art.

[0156] Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and / or uses of the invention and obvious modifications and equivalents thereof. Thus, from the foregoing description, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein.

[0157] It is to be understood that the present invention is susceptible to modifications, changes and adaptations by those skilled in the art. Such modifications, changes, adaptations are intended to be within the scope of the present invention.

[0158] EXAMPLES:

[0159] Example 1: Preparation of 2,2,2-Trifluoro-l-(3-nitro-phenyl)-ethanone (A-2)

[0160] (CF3CO)2O &

[0161] A-1 A-2

[0162] Method A:

[0163] A four necked glass reactor (2 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, was charged with ethylene dichloride (EDC) (300 mL) followed by nitrobenzene (100 g, 0.81 mol). Catalyst ZSM-5 (2.5 g) was added. Trifluoroacetic anhydride (200.2 g, 0.93 mol) was added dropwise over 30 mins and then the reaction mass refluxed for 8 hrs. After completion of the reaction, the reaction mass was filtered and the filtrate was poured slowly over saturated sodium bicarbonate solution and stirred for 30 mins. The organic layer was separated. Aqueous layer was washed with EDC (100 mL). The combined organic layer washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish 2,2,2-Trifluoro-l-(3-nitro-phenyl)-ethanone (A-2). After purification, HPLC purity (area): 95%, Yield: 135.3 g, 76 %.

[0164] Method B:

[0165] A four necked glass reactor (2 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, was charged with EDC (750 mL) followed by nitrobenzene (175 g, 1.42 mol). Catalyst ZSM-5 (8.75 g) was added. Trifluoroacetic acid (413.5 g, 3.55 mol) was added dropwise over 45 mins and then the reaction mass refluxed for 17 hrs. After completion of the reaction, the reaction mass was filtered and the filtrate was poured slowly over saturated sodium bicarbonate solution and stirred for 30 mins. The organic layer was separated. Aqueous layer was washed with EDC (100 mL). The combined organic layer washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish 2,2,2-Trifluoro-l-(3- nitro-phenyl)-ethanone (A-2). After purification, HPLC purity (area): 95%, Yield: 183.8 g, 59 %.

[0166] Example 2: Preparation of l-(3-Chloro-5-nitro-phenyl)-2,2,2-trifluoro-ethanone (A-3)

[0167] A-2 A-3

[0168] A pressure reactor was charged with acetic acid (250 mL) followed by 2,2,2-Trifluoro-l-(3- nitro-phenyl)-ethanone (157.9 g, 0.68 mol). Anhydrous ferric chloride (3.4 g, 0.02 mol) was added. The reactor was filled with chlorine gas and the pressure of chlorine gas was held at 6 Bar. The reaction was heated to 120° C for 16 hrs under constant stirring. After completion of the reaction, the excess chlorine gas was quenched. Ethylene dichloride (500 mL) was added to the reaction mass and it was poured slowly over aqueous sodium hydroxide and stirred for 30 mins. The organic layer was separated. Aqueous layer was washed with EDC (100 mL). The combined organic layer washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish l-(3-Chloro-5-nitro-phenyl)-2,2,2-trifluoro-ethanone (A- 3). After purification, HPLC purity (area): 92%, Yield: 112.9 g, 65 %.

[0169] Example 3: Preparation of l-(3,4-Dimethyl-phenyl)-ethanone (B-2)

[0170] B-1 B-2

[0171] A four necked glass reactor (5 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, calcium chloride guard tube was charged with EDC (2500 mL) followed by o-Xylene (526.3 g, 4.71 mol) and Aluminum chloride (512.7 g, 3.77 mol). The mixture was cooled to 10° C. Acetyl chloride (320.7 g, 4 mol) was added dropwise over 45 mins under vigorous stirring. After complete addition of acetyl chloride, the reaction mass was allowed to warm to room temperature and stirred for 3.5 hrs. After completion of the reaction, the reaction mass was slowly poured over ice-cold 10% HC1. After complete quenching, the mass was brought to room temperature. Organic layer was separated. The aqueous layer was washed with EDC (350 mL). The combined organic layer washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish) l-(3,4-Dimethyl-phenyl)-ethanone (B- 2). After purification, HPLC purity (area): 92%, Yield: 544.4 g, 78 %.

[0172] Example 4: Preparation of 4-Acetyl-2-methylbenzamide (B-3)

[0173] B-2 B-3

[0174] A four necked glass reactor (3 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, calcium chloride guard tube was charged with EDC (750 mL) followed by l-(3,4-Dimethyl-phenyl)-ethanone (B-2) (244.6 g, 1.52 mol), Monoethylene glycol (MEG) (500 g, 7.6 mol), and p-Toluenesulfonic acid (p-TSA) (5.4 g, 0.03 mol). The reaction mass was heated to 70-75° C for 7 hrs. After completion of the reaction, the reaction mass was cooled to room temperature, quenched with addition of water (500 mL). The organic layer was separated and washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to furnish 2-(3,4-Dimethyl-phenyl)-2-methyl- [l,3]dioxolane (ketal derivative of B-2). The weight of crude material: 239.4 g. The crude material was used without further purification for the next conversion.

[0175] A pressure reactor (2 lit) was charged with ethylene dichloride (300 mL) followed by 2-(3,4- Dimethyl-phenyl)-2-methyl-[l,3]dioxolane (180.4 g, 0.91 mol) followed by Cobalt (II) acetylacetone [(Co(acac)2] (2.46 g, 0.009), Tetra-n-butyl ammonium bromide (TBAB) (6.1 g, 0.018 mol). The pressure reactor was closed. The stirring was started. The reactor was flushed twice with oxygen. The reactor was filled with oxygen and pressure was taken to 5 bar. The reactor was heated to 110-115° C. After attaining the temperature, oxygen pressure was elevated to 10 Bar. The reaction was continued for 9 hrs till completion. After completion of the reaction, the reactor was cooled down to room temperature, excess oxygen was bubbled through water before opening of the reactor. Ethylene dichloride (EDC) was distilled out and the residue was poured on ice-cold NaOH solution (5M). The aqueous layer washed with EDC (200 mL). The aqueous layer was acidified with concentrated HC1 at lower temperature. The solid obtained was filtered and dried till constant weight to furnish 4-Acetyl-2-methyl-benzoic acid. HPLC purity (area): 98%, Yield: 139.6 g, 69 %.

[0176] A four necked glass reactor (5 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, Calcium chloride guard tube was charged with 4-Acetyl-2-methyl-benzoic acid (510.5 g, 2.18 mol) dissolved in ethylene dichloride (EDC) (1500 mL), followed by N,N- Dimethylformamide (DMF) (1.63 g) at room temperature. Thionyl chloride (583 g, 4.8 mol) was added dropwise over 45-50 mins under vigorous stirring at room temperature. After complete addition of thionyl chloride, the reaction mass was refluxed briefly (1 hr to 1.5 hr) to ensure complete conversion of acid to the acid chloride. The reaction mass was cooled to rt and diluted with additional EDC (350 mL). Aqueous ammonia was slowly added through the reaction mass using deep pipe. The complete reaction sequence was performed in well ventilated fume-hood. After completion of the reaction, it was quenched by pouring on ice- cold water. The Organic layer was separated. Aqueous layer was washed with EDC (200 mL). The combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to furnish 4-Acetyl-2- methylbenzamide (B-3). After purification, HPLC purity: 97%, Yield: 328.7 g, 85 %.

[0177] Example 5: Preparation of 4-(2-Bromo-acetyl)-2-methyl-benzamide (B-4)

[0178] A four necked glass reactor (2 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, Calcium chloride guard tube was charged with 4-Acetyl-2- methylbenzamide (189.5 g, 1.02 mol) dissolved in EDC (550 mL) followed by (Azobisisobutyronitrile) AIBN (6.9 g, 0.04 mol). A- Bro mo succinimide (NBS) (205 g, 1.12 mol) was added portion-wise at 40-45° C. After complete addition of NBS, the reaction mass was tired for 8 hr. After completion of the reaction, the reaction mass was filtered and the residue was washed with EDC (150 mL). The combined filtrate was washed with water (1 X 150 mL), brine (1 X 150 mL), dried over anhydrous sodium sulfate, filtered and concentrated at reduced pressure to furnish 4-(2-Bromo-acetyl)-2-methyl-benzamide. After purification, HPLC purity: 92%, yield: 197.7 g, 76%. Example 6: Preparation of 4-[3-(3-Chloro-5-nitro-phenyl)-4,4,4-trifluoro-but-2-enoyl]- 2-methyl-benzamide (C-l)

[0179] A-3 B-4

[0180] A three necked RB flask (1 Lit) fitted with thermometer pocket, thermometer, mechanical stirrer was charged with dry Toluene (150 mL) followed by triphenylphosphine (184.7 g, 0.69 mol) under nitrogen atmosphere. 4-(2-Bromo-acetyl)-2-methyl-benzamide (144.3 g, 0.55 mol) dissolved in dry Tetrahydrofuran (THF) (300 mL) and added in single lot at room temperature. Sodium methoxide powder (38 g, 0.69 mol) was added in 4 equal portions at RT. A deep yellow to brown colored reaction mass was observed. After complete addition of sodium methoxide, the reaction mass was stirred for 15 mins followed by dropwise addition of l-(3-Chloro-5- nitro-phenyl)-2,2,2-trifluoro-ethanone (147.4 g, 0.55 mol) dissolved in dry Toluene (450 mL). The gradual decolorization of the reaction was seen indicating the reaction progress. After stirring for 2 hr, the reaction was slowly poured on ice-cold brine solution. The organic layer was separated. Brine layer was washed with ethyl acetate (150 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to furnish 4-[3-(3-Chloro-5-nitro-phenyl)-4,4,4-trifluoro-but-2-enoyl]-2-methyl- benzamide (C-l). After purification, HPLC purity: 97%, yield: 186.8 g, 82%.

[0181] Example 7: Preparation of 4-[5-(3-Chloro-5-nitro-phenyl)-5-trifluoromethyl-4,5- dihydro-isoxazol-3-yl] -2-methyl-benzamide (C-2)

[0182] A four necked glass reactor (2 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, was charged with aqueous solution of hydroxylamine hydrochloride (26.5 g in 35 mL water, 0.37 mol) followed by aqueous sodium hydroxide (16.6 g in 35 mL water, 0.41 mol). This mixture is cooled to 5 to 10° C. Intermediate (C-l) (144.3 g, 0.34 mol) dissolved in methanol (MeOH) (450 mL) was added dropwise without allowing the reaction temperature to rise above 10° C. After complete addition, the reaction mass was allowed to warm to room temperature and stirred for 2 hrs. The reaction mass was cooled again to 10° C and HCI (67 g, 30%) was added slowly. After complete addition, the reaction mass allowed to warm to room temperature and then heated to 80° C for 7 hrs. After completion of the reaction, the pH of the reaction mass adjusted to 8 to obtain 4-[5-(3-Chloro-5-nitro-phenyl)-5- trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl-benzamide (C-2) as solid. The solid material was filtered, dried and recrystallized form IPA. After purification, HPLC purity: 96%, yield: 103 g, 71%.

[0183] Example 8: Preparation of 4-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro- isoxazol-3-yl]-2-methyl-benzamide (C-3)

[0184] C-2 C-3

[0185] In an autoclave reactor (2 Lit), 4-[5-(3-Chloro-5-nitro-phenyl)-5-trifluoromethyl-4,5-dihydro- isoxazol-3-yl]-2-methyl-benzamide (Intermediate C-2) (93.7 g, 0.21 mol) was charged followed by Methanol (200 mL). Catalyst 5% Pd / C (1.12 g) was charged carefully to this mixture. The autoclave was closed and then flushed with Nitrogen gas 3-4 times. Nitrogen gas was removed by applying a slight vacuum and then filled with Hydrogen gas. The pressure of hydrogen gas applied was 5 Kg / cm2. Stirring was started and continued. Whenever, the pressure of hydrogen drops below 5 Kg / cm2, hydrogen gas was refilled to make up the pressure. After completion of the reaction, hydrogen gas was vented out very carefully in water container. The reaction mass was filtered through celite and washed with methanol (2 X 50 mL). Combined methanolic layer was concentrated under vacuum to furnish 4-[5-(3-Amino- 5-chloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-methyl-benzamide. Crude weight: 70.3 g. This crude material was used for the next step.

[0186] In a four necked glass reactor (1 Lit) fitted with condenser, thermometer pocket, thermometer, mechanical stirrer, 4-[5-(3-Amino-5-chloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol- 3-yl]-2-methyl-benzamide (68.1 g, 0.16 mol) was dissolved in HC1 (88.1 g) and cooled to 0°C to 5° C. Sodium nitrite (12.5 g, 0.18 mol) dissolved in water was added dropwise without allowing the reaction mass temperature to rise above 5° C. After completion of the addition, the reaction was maintained at the same temperature for 30 mins. Cuprous chloride (19.7 g, 0.19 mol) was added in lots at the same temperature. After addition of Cuprous chloride, the reaction was allowed to warm to room temperature and monitored by TLC and HPLC. Evolution of Nitrogen was seen. After completion, ethylene chloride (250 mL) was added and the organic layer was separated. The aqueous layer was washed with EDC (1 X 50 mL). The combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated to furnish 4-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro- isoxazol-3-yl]-2-methyl-benzamide (C-3). After purification, HPLC purity: 95%, yield: 48.3 g, 75%.

[0187] Example 9: Preparation of Fluxametamide (I)

[0188] C-3 Fluxamitamide ( I )

[0189] A three necked RB flask (500 mL) fitted with thermometer pocket, thermometer, mechanical stirrer, anhydrous calcium chloride guard tube was charged A,A-Dimethylformamide (DMF) (100 mL). The RB flask was ice cooled and Phosphorous oxychloride (20.3 g, 0.13 mol) was added dropwise. An exothermic reaction occurred with the formation of the phosphorus oxychloridedimethylformamide complex. After complete addition of POCk, the reaction mass was stirred for 15 mins in ice bath followed by addition of 4-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5- dihydro-isoxazol-3-yl]-2-methyl-benzamide (C-3) (47.4 g, 0.11 mol) dissolved in DMF. The reaction was allowed to warm to room temperature and then heated at 75-80° C. After completion of the reaction, the reaction mass was carefully poured on crushed ice with continuous stirring. The pH of the solution was adjusted to 7-8 by addition of sodium acetate. The product was extracted in ethyl acetate (350 mL). The organic layer was washed with water (2 X 150 mL), brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated to furnish the residue (36.1 g).

[0190] The residue was dissolved in methanol (125 mL) and cooled in ice bath. Methoxylamine hydrochloride (6.8 g, 0.07 mol) was added as a solid. To this mixture, sodium hydroxide (3.1 g, 0.07 mol) in water (15 mL) was added dropwise. The reaction was allowed to warm to room temperature and stirred for 4 hr. After completion, the obtained solid was filtered and washed with water, followed by toluene to furnish crude Fluxametamide. The product was crystallized from 2-propanol twice. After purification, HPLC purity: 98.4 %, yield: 27.2 g, 85 % The present invention is more specifically explained by examples given above.

[0191] However, it should be understood that the scope of the present invention is not limited by the examples in any manner. It will be appreciated by any person skilled in this art that the present invention includes the given examples and further can be modified and altered without departing from the novel teachings and advantages of the invention which are intended to be included within the scope of the invention.

Claims

WE CLAIM:Claim 1: An improved process for the preparation of Fluxametamide of Formula (I), comprising: vii. reacting a compound, l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one of Formula (A-3), with 4-(2-bromoacetyl)-2-methylbenzamide of Formula (B-4), to obtain a compound, 4-[(2Z)-3-(3-chloro-5-nitrophenyl)-4,4,4-trifluorobut-2- enoyl]-2-methylbenzamide of Formula (C-l); viii. cyclizing the compound of Formula (C-l) in the presence of hydroxylamine hydrochloride and a suitable solvent followed by acid mediated cyclization to obtain a dihydroisoxazole compound, 4-[5-(3-chloro-5-nitrophenyl)-5-(trifluoromethyl)- 4,5-dihydro-l,2-oxazol-3-yl]-2-methylbenzamide of Formula (C-2); ix. hydrogenating the compound of Formula (C-2) in the presence of hydrogen and catalysts at suitable pressure and in the presence of a suitable solvent to yield the corresponding aniline which is further diazotized under standard conditions followed by treatment with chlorinating agent such as CuCl to obtain a compound, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-l,2-oxazol-3-yl]-2- methylbenzamide of Formula (C-3); and x. reacting the compound of Formula (C-3) in the presence of formylating agent followed by treatment with methoxyamine hydrochloride to obtain the compound Fluxametamide of formula (I).Claim 2: An improved process for the preparation of compound of l-(3-chloro-5-nitrophenyl)-2,2,2-trifluoroethan-l-one i.e., compound of Formula (A-3) as claimed in claim 1, comprising: xi. subjecting a compound, Nitrobenzene of Formula (A-l) to acylation in the presence of acylating agent and Lewis acids, to furnish a compound, of Formula (A -2), i.e.,2.2.2-trifluoro-l-(3-nitrophenyl)ethan-l-one; xii. reacting the compound of Formula (A-2), obtained in step (i) with halogenating agent to furnish a compound of Formula (A-3), i.e., l-(3-chloro-5-nitrophenyl)-2.2.2-trifluoroethan- 1 -one;Claim 3: An improved process for the preparation of compound of Formula (B-4), i.e., 4-(2- bromoacetyl)-2-methylbenzamide as claimed in claim 1, comprising: iv. subjecting a compound o-Xylene of Formula (B-l) to acylation in the presence ofan acylating agent and lewis acids to furnish a compound of Formula (B-2), i.e., 1- (3 ,4-dimethylphenyl)ethan- 1 -one. v. converting the compound of Formula (B-2) obtained in step (i) to its acid chloride in the presence of halogenating agents and suitable solvents after suitably protecting the carbonyl group of compound of Formula (B-2) under controlled oxidative conditions, followed by amidation to furnish a compound of Formula (B-3), i.e., 4- acetyl-2-methylbenzamide. vi. subjecting the compound of Formula (B-3) obtained in step (ii) to halogenation in the presence of halogenating agents and a suitable solvent to provide a compound of Formula (B-4), i.e., 4-(2-bromoacetyl)-2-methylbenzamide.Claim 4: The improved process as claimed in claims 1-3, wherein the acylating agent is selected from the group comprising Acetyl chloride, Acetic anhydride, Trifluoroacetyl chloride or trifluoroacetic anhydride, Trifluoroacetic acid or combination thereof.Claim 5: The improved process as claimed in claims 1-3, wherein the lewis acid is selected from the group comprising Zinc chloride (ZnCh), Aluminium Chloride (AlCh), Ferric Chloride (FeCF), Boron Trifluoride (BF3), Boron Trichloride (BCI3), Titanium tetrachloride (TiCU), Antimony Pentafluoride (SbFs), Copper Chloride (CuCh), p-Toluenesulfonic acid (p- TSA) any metal triflates or Zeolites or combination thereof.Claim 6: The improved process as claimed in claims 1-3, wherein the halogenating agent is selected from the group comprising of a chlorinating agent, brominating agent, fluorine, iodine, etc. or combination thereof.Claim 7 : The improved process as claimed in claim 6, wherein the chlorinating agent is selected from the group comprising chlorine gas or chlorine in combination with acetic acid, thionyl chloride, oxalyl chloride, phosphorous trichloride or phosphorous pentachloride, or N- chlorosuccinimide, Cuprous chloride or combination thereof.Claim 8: The improved process as claimed in claim 6, wherein the brominating agent is selected from the group comprising of an aqueous HBr, KBr, or A-bromosuccinimide (NBS) in combination with H2O2 & H2SO4 or combinations thereof.Claim 9: The improved process as claimed in claims 1-3, wherein the halogenating agent is further selected from selected from the group comprising chlorine gas or N-Chlorosuccinimide, Thionyl chloride, Oxalyl chloride, phosphorus tribromide, X2, HX, wherein X = Cl, Br, I, Phosphorous trichloride, sulfuryl chloride or phosphorous pentachloride, Cuprous chloride or chlorine, bromine, fluorine, iodine in combination with acetic acid, hydrogen, H2O2, potassium, and H2SO4 or combination thereof.Claim 10: The improved process as claimed in claims 1-3, wherein the suitable solvent is selected from the group comprising ethylene dichloride (EDC), methylene dichloride (MDC), chlorobenzene, methanol, ethyl acetate, acetic acid, N-dimethylformamide, benzene, chloroform, 1, 4-dioxane, diethyl ether, hydrogen peroxide, o-dichlorobenzene, carbon tetrachloride, chlorobenzene, dichlorobenzene, tetrahydrofuran and acetonitrile, acetone, dimethylsulfoxide, cyclohexane, hexane, heptane, toluene, xylene, phosphorous oxychloride , isopropanol, 2-propanol, ethylene chloride, Tetrahydrofuran (THF), toluene, brine, sodium sulfate, other metal sulfates or combination thereof.Claim 11: The improved process as claimed in claims 1-3, wherein the process of acid- mediated cyclization is carried by using mineral acid such as HC1.Claim 12: The improved process as claimed in claims 1-3, wherein the suitable pressure is in range from the atmospheric pressure to 50 Bar pressure.Claim 13: The improved process as claimed in claims 1-3, wherein the formylating agent is selected from the group comprising para-formaldehyde, formalin, formic acid, methyl formate, phosphorous oxychloride, A-di methyl formamide, diazomethane, cyanogen bromide, hydrogen cyanide or combination thereof.Claim 14: The improved process as claimed in claims 1-3, wherein, the process of amidation is carried by the reagents selected from the group comprising ammonia gas, or aqueous ammonia or ammonium acetate or ammonium formate or combination thereof.Claim 15: The improved process as claimed in claims 1-3, wherein the catalyst is selected from the group comprising 5-10% Pd on Charcoal or 5% Pt on Charcoal, ZSM-5, p-Toluenesulfonic acid (p-TSA), Cobalt (II) acetylacetone [(Co(acac)2] , Tetra-n-butyl ammonium bromide(TBAB), (Azobisisobutyronitrile) AIBN or combination thereof.Claim 16: A process for preparing agrochemical composition comprising Fluxametamide of Formula (I) as obtained by the process claimed in claims 1-15.Claim 17: An agrochemical composition, wherein the composition comprises at least a bioactive effective amount of Fluxametamide of Formula (I) as obtained by the process claimed in claims 1-15.Claim 18: The agrochemical composition as claimed in claim 17, which further comprises one of more agrochemically acceptable excipients.Claim 19: A process for preparing the agrochemical composition comprising Fluxametamide of Formula (I) as claimed in claims 17-18.

Images